Risk-stratified early intervention for paucisymptomatic GOLD I–II chronic obstructive pulmonary disease: breaking the diagnostic deadlock

Chronic obstructive pulmonary disease (COPD) remains a leading global cause of chronic respiratory disability, with a substantial share of disease burden originating from undiagnosed mild-to-moderate airflow limitation (1). Clinical practice has long depended on patient-reported respiratory symptoms to trigger COPD workup, yet mounting real-world evidence demonstrates that numerous individuals with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I–II COPD minimise physical activity to avoid exertional dyspnoea, resulting in a paucisymptomatic phenotype that evades routine clinical recognition (2). This persistent diagnostic deadlock creates a critical clinical paradox: substantial pathological remodelling of small airways and lung parenchyma may progress silently before patients develop obvious cough, sputum production or breathlessness (3). Existing guidelines hold divergent standpoints regarding population-level screening, creating uncertainty for frontline clinicians on whom to test and when to initiate pharmacotherapy (4). Against this background, the international multi-expert consensus statement by Guan and coworkers delivers a timely real-world-oriented framework addressing detection and management of paucisymptomatic GOLD I–II COPD (5). This editorial contextualizes their consensus proposals against current evidence base, weighs practical and scientific constraints, interprets underlying disease pathophysiology, and maps actionable paths for clinical practice and future investigation.

The international expert panel synthesised contemporary epidemiological data, novel multi-dimensional diagnostic criteria, community-based spirometry innovations and accumulated clinical trial findings to formulate whole-chain management suggestions for paucisymptomatic GOLD I–II COPD (5). Rejecting exclusive reliance on symptom-based triggers for diagnosis, the manuscript endorses a multi-dimensional diagnostic schema integrating post-bronchodilator spirometry together with secondary markers including emphysema, bronchial wall thickening, quality-of-life impairment and chronic bronchitis (5,6). The authors highlight simplified artificial-intelligence-augmented portable spirometry as a feasible community-level screening tool targeted specifically at high-risk groups: smokers, people with occupational pollutant exposure and individuals with prior pulmonary tuberculosis, rather than unselected general-population adults (5). Balancing concerns about overtreatment in GOLD-I subjects, the consensus cites outcomes from the Tie-COPD trial confirming bronchodilator-associated improvements in lung function and exacerbation risk among community-detected mild-moderate COPD participants, even though consistent slowing of annual forced expiratory volume in 1 second (FEV₁) decline was not achieved across the full cohort (5,7). Central to their proposal is a risk-stratified tiered therapeutic objective system, separating short-term symptom relief, intermediate-term exacerbation prevention and long-term preservation of lung function, alongside calls for multidisciplinary cross-sector collaboration covering public health, digital healthcare, rehabilitation and health economics (5). Importantly, the panel advocates greater adoption of composite endpoints such as clinically important deterioration (CID) for early-COPD clinical trials, given that isolated FEV₁ measurements cannot fully capture real-world disease activity (5,8).

This consensus work delivers several meaningful conceptual advances that fill gaps within everyday respiratory practice. Most notably, it draws a clear distinction between universal mass screening for all asymptomatic adults and targeted proactive case-finding among well-defined high-risk populations (5). This distinction eases the tension with existing guidance such as the United States Preventive Services Task Force recommendation against unselected population COPD screening, which has frequently created confusion for primary-care physicians (4). Simplified prebronchodilator spirometry with AI-driven quality-control addresses major practical bottleneck: conventional spirometry is labour-intensive and time consuming, requiring skilled staff, which limits widespread deployment in resource-limited community settings globally (5,9). Furthermore, the article aligns with recent GOLD-Global Lung Initiative joint statements that move away from sole dependence upon FEV₁ for grading COPD severity, acknowledging the heterogeneity of early-stage disease (5,10). The risk-stratified management framework avoids rigid one-size-fits-all pharmacotherapy; low-risk paucisymptomatic GOLD-I patients may receive close surveillance without drugs, while intensified therapy is reserved for individuals displaying high-risk features such as rapid lung-function decline or frequent exacerbations (5,11). Such stratification is clinically vital given ongoing debates around overtreatment in mild COPD, where robust evidence for long-term disease-modifying drug effects remains incomplete (11). Adoption of composite endpoints like CID also helps bridge the gap between clinical trial measurements and patient-centred real-world outcomes (8).

From an editorial perspective, medical professionals in this country—home to approximately 18% of the global population and contributing roughly 18–19% of world nominal gross domestic product—are fully entitled to put forward responsible voices for the health of their own population grounded in local real-world clinical evidence. Journal of Thoracic Disease serves as an open academic venue that welcomes academic debate and constructive contention, which collectively fuels the shared prosperity of global science and research.

Even so, several nontrivial scientific and implementation-related caveats must be kept in mind before widespread adoption of these consensus recommendations. First, performance metrics for the newly-proposed multi-dimensional diagnostic criteria have been mainly validated within North American and Chinese cohorts; diagnostic sensitivity and specificity remain inadequately characterised in low-and-middle-income populations with distinct risk factor profiles (5,6). Second, community-deployed simplified spirometry will inevitably yield false-positive screening results. Without robust local confirmatory diagnostic pathways, widespread rollout risks misclassification and unnecessary medication initiation (9). Third, therapeutic evidence gaps persist. While Tie-COPD demonstrated symptomatic and exacerbation-related benefits of tiotropium in early-stage COPD, convincing proof that inhaled pharmacotherapy can durably retard FEV₁ loss for unselected paucisymptomatic GOLD-I subjects is still lacking (5,7). Approximately half of COPD cases stem from failure to attain optimal peak lung function in early adulthood instead of accelerated lung function decline in adult life; therapeutic responses for this distinct subgroup remain poorly studied (5,12). Fourth, formidable real-world implementation barriers persist. Shortages of primary-care respiratory training, insufficient reimbursement for community spirometry, and low public health literacy will slow translation, especially in resource-constrained regions (5). Finally, CID as a composite trial endpoint still awaits thorough real-world validation and regulatory recognition for routine community patient monitoring (5,8).

These practical challenges are rooted in the intrinsic biological and epidemiological heterogeneity of early-stage COPD. Subclinical small-airway remodeling precedes measurable spirometric airflow obstruction in most disease trajectories, accumulating silently without overt patient-reported discomfort (13). Many paucisymptomatic patients adopt reduced physical activity to evade exertional dyspnoea, creating a clinical phenotype that masks underlying progressive pathological change (3). The two divergent lung-function life-course trajectories leading to COPD—accelerated adulthood FEV₁ decline versus insufficient peak lung growth—may respond dissimilarly to pharmaceutical and non-pharmaceutical interventions, yet simple clinical tools to reliably differentiate these two subgroups are not yet available (12). Beyond tobacco smoking, occupational pollutant exposure and prior tuberculosis also shape disease progression risk, expanding the scope of populations who merit targeted case-finding (14). Even mild COPD exacerbations drive irreversible lung-function loss and amplify cardiovascular risk independent of baseline symptom burden; this provides the core biological rationale for identifying high-risk paucisymptomatic patients before severe clinical events manifest (15).

Translating this expert consensus into routine clinical and public-health practice requires coordinated adjustments across clinical workflows, research agendas and health policy. For practising clinicians, spirometry should no longer be reserved exclusively for patients complaining of dyspnoea; targeted case-finding ought to be incorporated into routine health assessments for high-risk middle-aged adults (5). Risk stratification should guide therapeutic decisions: observation without pharmacotherapy remains reasonable for low-risk paucisymptomatic GOLD-I COPD, whereas intensified treatment should be offered to those demonstrating rapid lung-function deterioration, recurrent exacerbations or impaired quality of life (5,11). Smoking cessation continues to be the most impactful nonpharmacological intervention across all early-stage subgroups (5).

For the research community, multiethnic prospective community cohorts are urgently needed to externally validate multi-dimensional diagnostic criteria across diverse global populations (6). Randomised controlled trials should deliberately enrich enrolment of paucisymptomatic GOLD-I participants to clarify which patient subgroups achieve durable disease-modifying benefits from inhaled therapy (5). Additional investigation is required to refine composite endpoints such as CID for primary-care use, and to define the incremental diagnostic yield of oscillometry and chest computed tomography as supplementary screening modalities (8). Implementation-science studies should evaluate cost-effectiveness of artificial intelligence (AI) enhanced portable spirometry under different healthcare systems and address barriers including workforce shortages and reimbursement deficits (9). Rapid lung-function decline and heterogeneous treatment requirements among mild-moderate COPD populations deserve greater attention during future guideline revisions (16), as reflected in multiple observational studies published in Journal of Thoracic Disease (14,17).

In summary, the consensus statement by Guan and colleagues provides a pragmatic, balanced framework for addressing paucisymptomatic GOLD I–II COPD (5). It highlights the necessity of moving beyond symptom-only diagnostic paradigms towards risk-targeted case-finding and stratified management. Nevertheless, multiple unresolved evidence gaps and substantial implementation obstacles remain, calling for further high-quality real-world observational research and well-designed clinical trials across varied global populations.

Supplementary

The article’s supplementary files as

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.